Access Resources
801 - 825 of 7540 Results
Title
Year
- Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)2022RESTRICTEDTitle: Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903320.23411.f9Best OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S40.full.pdfCitation Count: 0
-
RESTRICTEDTitle: Substitution of PINK1 Gly411 modulates substrate receptivity and turnoverJournal Name: AutophagyPublisher: Informa UK LimitedVol: 19Issue #: 6Start Page: 1711End Page: 1732Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1080/15548627.2022.2151294Best OA location URL: https://doi.org/10.1080/15548627.2022.2151294Citation Count: 6
- The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis2022RESTRICTEDTitle: The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor EncephalitisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903316.50895.83Best OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S39.full.pdfCitation Count: 1
- Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-Encephalitis2022RESTRICTEDTitle: Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-EncephalitisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903424.19914.85Citation Count: 0
-
RESTRICTEDTitle: Synapsin III Regulates Dopaminergic Neuron Development in VertebratesJournal Name: CellsPublisher: MDPI AGVol: 11Issue #: 23Start Page: 3902End Page: 3902Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3390/cells11233902Best OA location URL: https://www.mdpi.com/2073-4409/11/23/3902/pdf?version=1669977075Citation Count: 2
-
RESTRICTEDTitle: Agglomerative and divisive hierarchical Bayesian clusteringJournal Name: Computational Statistics & Data AnalysisPublisher: Elsevier BVVol: 176Issue #:Start Page: 107566End Page: 107566Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.csda.2022.107566Citation Count: 3
- Anionic lipid vesicles have differential effects on the aggregation of early onset-associated α-synuclein missense mutants2022RESTRICTEDTitle: Anionic lipid vesicles have differential effects on the aggregation of early onset-associated α-synuclein missense mutantsJournal Name: Journal of Biological ChemistryPublisher: Elsevier BVVol: 298Issue #: 12Start Page: 102565End Page: 102565Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.jbc.2022.102565Best OA location URL: http://www.jbc.org/article/S0021925822010092/pdfCitation Count: 1
-
RESTRICTEDTitle: Bile acids and neurological diseaseJournal Name: Pharmacology & TherapeuticsPublisher: Elsevier BVVol: 240Issue #:Start Page: 108311End Page: 108311Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1016/j.pharmthera.2022.108311Best OA location URL: https://doi.org/10.1016/j.pharmthera.2022.108311Citation Count: 12
- Biomarkers and non-motor symptoms as a function of motor symptom asymmetry in early Parkinson's disease2022RESTRICTEDTitle: Biomarkers and non-motor symptoms as a function of motor symptom asymmetry in early Parkinson's diseaseJournal Name: NeuropsychologiaPublisher: Elsevier BVVol: 177Issue #:Start Page: 108419End Page: 108419Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.neuropsychologia.2022.108419Best OA location URL: https://doi.org/10.1016/j.neuropsychologia.2022.108419Citation Count: 6
- Brain network characteristics and cognitive performance in motor subtypes of Parkinson's disease: A resting state fMRI study2022RESTRICTEDTitle: Brain network characteristics and cognitive performance in motor subtypes of Parkinson's disease: A resting state fMRI studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 105Issue #:Start Page: 32End Page: 38Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.10.027Citation Count: 2
- Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic2022RESTRICTEDTitle: Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemicJournal Name: Disease Models & MechanismsPublisher: The Company of BiologistsVol: 15Issue #: 12Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1242/dmm.049755Best OA location URL: https://doi.org/10.1242/dmm.049755Citation Count: 0
-
RESTRICTEDTitle: Comparison of manual and automated measures of walking speed: Distance and pace matterJournal Name: Experimental GerontologyPublisher: Elsevier BVVol: 170Issue #:Start Page: 111987End Page: 111987Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.exger.2022.111987Best OA location URL: https://doi.org/10.1016/j.exger.2022.111987Citation Count: 2
- Deciphering the molecular mechanism and crosstalk between Parkinson's disease and breast cancer through multi-omics and drug repurposing approach2022RESTRICTEDTitle: Deciphering the molecular mechanism and crosstalk between Parkinson's disease and breast cancer through multi-omics and drug repurposing approachJournal Name: NeuropeptidesPublisher: Elsevier BVVol: 96Issue #:Start Page: 102283End Page: 102283Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.npep.2022.102283Citation Count: 6
- Effective R2 relaxation rate, derived from dual-contrast fast-spin-echo MRI, enables detection of hemisphere differences in iron level and dopamine function in Parkinson’s disease and healthy individuals2022RESTRICTEDTitle: Effective R2 relaxation rate, derived from dual-contrast fast-spin-echo MRI, enables detection of hemisphere differences in iron level and dopamine function in Parkinson’s disease and healthy individualsJournal Name: Journal of Neuroscience MethodsPublisher: Elsevier BVVol: 382Issue #:Start Page: 109708End Page: 109708Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.jneumeth.2022.109708Best OA location URL: https://doi.org/10.1016/j.jneumeth.2022.109708Citation Count: 4
- Epidemiology meets toxicogenomics: Mining toxicologic evidence in support of an untargeted analysis of pesticides exposure and Parkinson’s disease2022RESTRICTEDTitle: Epidemiology meets toxicogenomics: Mining toxicologic evidence in support of an untargeted analysis of pesticides exposure and Parkinson’s diseaseJournal Name: Environment InternationalPublisher: Elsevier BVVol: 170Issue #:Start Page: 107613End Page: 107613Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.envint.2022.107613Best OA location URL: https://doi.org/10.1016/j.envint.2022.107613Citation Count: 5
-
RESTRICTEDTitle: Functional Interaction Between α-Synuclein and Nurr1 in Dopaminergic NeuronsJournal Name: NeurosciencePublisher: Elsevier BVVol: 506Issue #:Start Page: 114End Page: 126Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuroscience.2022.10.011Citation Count: 0
- Impact of the COVID-19 Pandemic on the Behavioral Health of People With Intellectual and Developmental Disabilities2022RESTRICTEDTitle: Impact of the COVID-19 Pandemic on the Behavioral Health of People With Intellectual and Developmental DisabilitiesJournal Name: Psychiatric ServicesPublisher: American Psychiatric Association PublishingVol: 73Issue #: 12Start Page: 1389End Page: 1392Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1176/appi.ps.202100524Citation Count: 8
- Impairment of amacrine starburst cells and their synaptic contacts with dopaminergic cells could explain motion perception disturbances in Parkinson's disease2022RESTRICTEDTitle: Impairment of amacrine starburst cells and their synaptic contacts with dopaminergic cells could explain motion perception disturbances in Parkinson's diseaseJournal Name: Acta OphthalmologicaPublisher: WileyVol: 100Issue #: S275Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/j.1755-3768.2022.0786Citation Count: 0
- Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s disease2022RESTRICTEDTitle: Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s diseaseJournal Name: Cell Stem CellPublisher: Elsevier BVVol: 29Issue #: 12Start Page: 1637End Page: 1652.e6Publication Date:Open Access(OA) Status: RESTRICTEDLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.stem.2022.11.010Best OA location URL: https://doi.org/10.1016/j.stem.2022.11.010Citation Count: 41
-
RESTRICTEDTitle: Machine learning‐based prediction of cognitive outcomes in de novo Parkinson's diseaseJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 18Issue #: S5Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/alz.067067Best OA location URL: http://bura.brunel.ac.uk/bitstream/2438/27655/1/FullText.pdfCitation Count: 0
-
RESTRICTEDTitle: Major advances in Parkinson's disease over the past two decades and future research directionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1076End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3Citation Count: 4
- Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology2022RESTRICTEDTitle: Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiologyJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 175Issue #:Start Page: 105925End Page: 105925Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-nd, cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nbd.2022.105925Best OA location URL: https://doi.org/10.1016/j.nbd.2022.105925Citation Count: 7
- Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS)2022RESTRICTEDTitle: Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS)Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 105Issue #:Start Page: 139End Page: 144Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.08.002Best OA location URL: http://www.prd-journal.com/article/S1353802022002553/pdfCitation Count: 6
-
RESTRICTEDTitle: Nano drug delivery systems for antisense oligonucleotides (ASO) therapeuticsJournal Name: Journal of Controlled ReleasePublisher: Elsevier BVVol: 352Issue #:Start Page: 861End Page: 878Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jconrel.2022.10.050Citation Count: 22
-
RESTRICTEDTitle: Non-REM sleep with hypertonia in Parkinsonian Spectrum Disorders: A pilot investigationJournal Name: Sleep MedicinePublisher: Elsevier BVVol: 100Issue #:Start Page: 501End Page: 510Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.sleep.2022.09.025Best OA location URL: https://doi.org/10.1016/j.sleep.2022.09.025Citation Count: 5